Latest News

F2G bags €50.8m financing to advance olorofim

Aspergillus spores could become dangerous for people with a weakened immune system. © CDC


by tg

UK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors.

The €50.8m financing round was led by Cowen Healthcare Investments and includes strong participation from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences.

The Manchester and Vienna-based company announced it will use the proceeds to finance the ongoing Phase IIb proof-of concept study of its antifungal compound olorofim (F901318) and preparatory work for its commercialisation. F901318, a dihydrorotate dehydrogenase (DHODH) blocker, is in a Phase 2b open-label study focussing on rare and resistant life-threatening opportunistic fungal infections, such as invasive aspergillosis, scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis, and valley fever. Olorofim, F2G’s lead compound from the novel drug class of orotomides that block fungal de novo pyrimidine synthesis, could represent a market opportunity in excess of US$6bn. 

Meatable teams up with Royal DSM

The two Dutch companies have entered into a joint development agreement. DSM and Meatable will work on the development of meat-like taste and texture...

BioNTech takes over cancer immunotherapy platform

After its impressive performance bringing the first mRNA vaccine for COVID-19 to market, BioNTech SE is strengthening its portfolio in the area of...

Swiss Biotech Day shows great biopharma ambitions

The Swiss biotech industry is not letting the COVID 19 pandemic slow it down - this was shown at the first live Swiss Biotech Day since the beginning...

Byondis and Glycotope merge platforms to target carbohydrates

The goal of this partnership is to discover and develop antibodies that target specific tumour-associated protein/carbohydrate combined...

Spectricity raises €14m in Series B round

Atlantic Bridge, Capricorn Fusion China Fund, Shanghai Semiconductor Equipment and the Material Fund (SSMEF) led the Series B financing round...

AXA IM Alts raises €1.9bn European Life Sciences Fund

The capital was raised over the last seven months, with commitments to a significantly oversubscribed fund raise from a range of clients from North...

Foundation launches Harvard research hub

The foundation and the Broad Institute have joined up to launch the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, an initiative...